Device Support and Concierge Services for Commercial Patient Access and Adherence Support Programs

Why device support and concierge services are suddenly a board-level topic

Commercial patient support programs used to be defined mainly by reimbursement workflows. That is still true, but the center of gravity is shifting. Three industry forces are converging:

Therapies are increasingly designed for at-home administration and self-management, with delivery devices becoming part of the “product experience.” Fierce Pharma’s coverage of Novartis’ push to convert biologics into at-home injectables is one example of the broader direction of travel, including patient self-administration “after proper training.”

Commercial models are also evolving toward more direct-to-patient pathways for affordability and fulfillment. In July 2025, Fierce Pharma reported that Bristol Myers Squibb and Pfizer established “Eliquis 360 Support,” a direct-to-patient online option positioned to help uninsured, underinsured, and cash-pay patients access a discounted price. BioSpace described the same program as an expansion of an existing patient support program used for health education and insurance support, extended to include direct-to-patient sales.

Finally, adherence remains a persistent and expensive challenge across chronic therapies. CDC summaries note that 20% to 30% of prescriptions are never filled and that about 50% of chronic disease medications are not taken as prescribed. These realities create a simple commercial truth: access friction and device friction both contribute to drop-off, and diluting either friction can protect outcomes and revenue.

What “device support” means in commercial patient support programs

Device support is best understood as structured, patient-facing education and troubleshooting that helps someone use a therapy safely and confidently within the labeled instructions, especially when administration happens at home.

This work matters because device-enabled therapies often include steps that must be performed correctly to avoid harm or loss of benefit. FDA’s human factors guidance emphasizes designing and evaluating devices to reduce use error and resulting harm, reinforcing how “use” can be a safety variable, not just a convenience feature. FDA’s Home Use Device Initiative similarly highlights the need for devices intended for home settings to be designed, tested, and labeled with user-friendly instructions for home care recipients and caregivers, to reduce errors that can occur during use.

In practical program terms, device support commonly includes a blend of: – First-dose readiness education (what supplies are needed, how to store and handle the product, and what to do if something appears wrong) – Live or virtual training for self-administration, using “teach-back” methods so the patient demonstrates understanding – Reinforcement (short follow-ups after initiation, when many use questions emerge) – Ongoing troubleshooting (device questions, missed doses, travel storage, replacement process for malfunction, and safe disposal steps where applicable) – Escalation pathways (when to pause and contact the prescriber; when to report product complaints or adverse events through the sponsor’s defined process)

A key boundary: device support should be anchored to approved labeling and “adequate directions for use,” rather than improvising new instructions. FDA device labeling requirements and related concepts are codified in federal regulation (21 CFR Part 801).

What “concierge services” mean in access and adherence support

Concierge services are the operational services that remove non-clinical friction so patients can start and stay on therapy. In commercial programs, this typically spans enrollment support, benefits investigation, prior authorization support, coordination with specialty pharmacy or distribution partners, affordability navigation, and structured follow-up.

This matters because administrative delays can translate into clinical harm and avoidable attrition. A Johns Hopkins-led review across 25 U.S. studies found prior authorization requirements are associated with delays in care and multiple categories of harm, including preventable hospitalizations; the findings were published September 3, 2025 in The American Journal of Medicine. [8] Even when prior authorization is clinically appropriate, the operational burden is real and the patient experience is often fragile.

Concierge services also increasingly intersect with affordability and fulfillment models. In the Eliquis example, BioSpace notes that the Eliquis 360 Support program was already used to provide health education and insurance help, and was expanded to reduce out-of-pocket costs for uninsured and self-pay patients through direct-to-patient access. [3] That is an access play, but it also changes what “support” must deliver: more navigation, more clarity, fewer handoffs.

Where device support and concierge services overlap

The strongest commercial programs do not run “device training” as a standalone widget. They design a single patient journey where access steps and device steps are orchestrated in the right order, with minimal repetition and clear handoffs.

A useful way to frame it is by time-window:

Pre-start (from referral to shipment): confirm enrollment and consent, resolve payer requirements, coordinate fulfillment, then schedule training at the moment the patient will actually have the product in hand. This is also where expectations are set about what support can and cannot do.

Start week (first dose): deliver structured training that aligns with labeling, including how to recognize common problems and what triggers a call to the provider. For device-enabled therapies, this is often the highest-leverage moment for confidence.

Stabilization (first 30 to 60 days): run proactive check-ins tied to known friction points, such as first refill, side-effect questions, or routine mistakes. CDC notes adherence is multifactorial and complex, and highlights that combining multiple strategies is often needed rather than relying on a single “silver bullet.”

Sustainment: transition to lighter-touch reminders and patient-preferred channels, but keep rapid access to a human when a device or coverage issue arises.

For context, Serva Health’s commercial patient support explicitly ties this continuum together, describing support “from awareness to access to education to adherence,” including capabilities like virtual injection training and coordination work that fits alongside hubs, specialty pharmacies, and payer workflows.

Compliance and risk guardrails executives should not ignore

High-touch support can be a differentiator, but it also requires careful governance.

First, regulators and prosecutors scrutinize programs that look like they provide “something of value” to influence prescribing or coverage decisions. In 2025, Fierce Pharma reported on a Texas lawsuit alleging that “free patient-care services” and reimbursement support services functioned as improper inducements; the reporting underscores that support services can become part of enforcement narratives even when companies dispute the claims.

Second, Office of Inspector General (OIG) guidance on patient assistance programs, while focused on federal health care program beneficiaries, provides a durable compliance lens. OIG has warned that manufacturer-operated assistance tied to subsidizing a company’s own products for Medicare Part D presents heightened fraud and abuse risk, even as it recognizes lawful avenues for helping patients access medically necessary drugs. OIG’s supplemental guidance also cautions that charity PAPs that are not sufficiently independent from manufacturer donors can create risk, including acting as a conduit to induce prescriptions.

Third, privacy and security have become operational imperatives. Fierce Pharma reported that a technical flaw resulted in unauthorized access to personal information tied to a large patient assistance program, highlighting the sensitivity of data collected in support workflows.

Closing thought

Device-enabled therapies and direct-to-patient access models increase the number of steps between “prescription written” and “therapy working.” Device support and concierge services, designed as one journey, help reduce abandonment, improve patient confidence, and protect outcomes, while staying aligned with labeling, fraud-and-abuse guardrails, and modern privacy expectations.

For readers who want an example of how commercial programs describe this integrated approach, Serva Health’s overview of its commercial patient support programs provides additional context on common service components (education, access support, adherence check-ins, and omnichannel communications).